Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 51% of JPMA Member Firms Have Documented Compliance Programs
September 24, 2001
- Makers Outsource More OTC Drug Marketing Activities
September 24, 2001
- FJPWA Decides to Cooperate in Market Price Survey
September 24, 2001
- OTC NEWS IN BRIEF
September 24, 2001
- Wholesalers' Bargaining Ability to Be Tested in 2002
September 24, 2001
- WORLD NEWS IN BRIEF
September 24, 2001
- BUSINESS NEWS IN BRIEF -1-
September 24, 2001
- P450 DB Provides Valuable Information on Drug Interactions: FQS, Shionogi
September 24, 2001
- IFN Alfacon, Insulin Aspart to Be Launched by Year-end
September 24, 2001
- Ono Discovers Promising CCR5 Receptor Antagonist Candidates
September 24, 2001
- BUSINESS NEWS IN BRIEF -2-
September 24, 2001
- Quintiles, Medical Corporation LTA Form PI Scientific Alliance
September 24, 2001
- BUSINESS NEWS IN BRIEF -3-
September 24, 2001
- Sysmex: Immune Agglutination Determination System PAMIA-40i
September 24, 2001
- Korosho to Assess Pros & Cons in Promoting R&D of New Technology: HIB Director
September 24, 2001
- M&A Inevitable for Japanese Drug Companies: Nikko Solomon's Analyst
September 24, 2001
- FY2001 Korosho White Paper Stresses Importance of Social Security as Safety Net
September 24, 2001
- 9 Active Ingredients to Be Approved in September
September 24, 2001
- PMSB to Take Measures to Ensure Quality of Imported Medical Devices
September 24, 2001
- REGULATORY NEWS IN BRIEF
September 24, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…